Cardiology 

• ¬ Dilated Myocardiopathy. Clinical trial titled "Effect of intracoronary infusion of bone marrow progenitor cells on myocardial regeneration in patients with dilated myocardiopathy. Clinical-biological study", with code TCMR0007/06 and EudraCT: 2007-003088-36. Site participating in this trial: Hospital U. Reina Sofía in Córdoba. It had been planned to recruit 30 patients with dilated miocardiopathy. Patients are treated with mononuclear autologous stem cell derived from bone marrow.
• ¬ Acute myocardial infarction.  Clinical trial titled " Myocardial regeneration after intracoronary implantation of autologous bone marrow stem cellsⁱ in patients with acute myocardial infarction with anterior localization", with code CM009/05. Site participating in this trial: Hospital U. Reina Sofía de Córdoba. It had been planned to recruit 30 patients with acute myocardial infarction. Patients are treated with mononuclear autologous stem cell derived from bone marrow.
• ¬ Chronic ischemic cardiopathy.  Clinical trial titled "Phase II clinical trial about the effect of autologous bone marrow stem cells intracoronary infusion over the functional recovery in patients with anterior myocardial infarction and severe depression of the left ventricular function", with code CMMo/CIC/2009 and EudraCT: 2009-016599-66. Site participating in this trial: Hospital U. Reina Sofía in Córdoba. It has been planned to recruit 20 patients with anterior chronic infarction. Patients are treated with mononuclear autologous stem cell derived from bone marrow.

Neurology 

• ¬ Multiple Sclerosis. Clinical trial titled "Multicentric, randomized, placebo-controlled, phaseI/II clinical trial, to evaluate the safety and feasibility of therapy with two different doses of autologous mesenchymal stem cellsⁱ from adipose tissueⁱ (CetMAd) in patients with secondary progressive multiple sclerosis, who do not appropriately respond to registered treatments", with code CMM/EM/2008 and EudraCT: 2008-004015-35. Sites participating in this trial: Hospital U. Carlos Haya in Málaga and Hospital U. Virgen Macarena (in collaboration with Hospital San Lázaro) in Sevilla. It had been planned to recruit 30 patients with multiple sclerosis. Patients are treated with autologous mesenchymal stem cell derived from the fat tissue. This investigational product will be manufactured in collaboration with the GMP facilities in the Centro Andaluz de Biología Molecular y Medicina Regenerativaⁱ (CABIMER- Andalusian Centre for Molecular Biology and Regenerative Medicineⁱ) in Sevilla.
• ¬ Stroke. Clinical trial titled "Reader-binded open study of the efficacy of autologous bone marrow mononuclear cells in cell regeneration in patients with acute ischemic stroke of the Middle Cerebral Artery", phase I/II with code TCI0107 and EudraCT: 2007-003700-36. Sites participating in this trial: Hospital Central de Asturias in Oviedo and Hospital U. Virgen del Rocío in Sevilla. It has been planned to recruit 20 patients with acute stroke. Patients are treated with mononuclear autologous stem cell derived from bone marrow.
• ¬ Multiple Sclerosis. Clinical trial titled "Multicentric, randomized, semi-crossed, double blind, phase I/II clinical trial, to evaluate the safety and feasibility of therapy with mesenchymal stem cells from autologous bone marrow in patients with multiple sclerosis", with code CeTMMo/EM/2010 and EudraCT: 2010-023368-42. Sites participating in this trial: Hospital Universitario Reina Sofía in Córdoba, Hospital Universitario Carlos Haya in Málaga and Hospital Universitario Virgen Macarena in Sevilla. It has been planned to recruit 30 patients with multiple sclerosis. Patients are treated with autologous mesenchymal stem cell derived from bone marrow. This investigational product will be manufactured in collaboration with the GMP facility in the Hospital Universitario Reina Sofía in Córdoba.
• ¬ Amyotrophic lateral sclerosis. Clinical trial titled "Multicentric, randomized, placebo controlled, triple blinded, phase I/II clinical trial, to evaluate the safety feasibility and evaluation of the intravenous therapy with autologous mesenchymal stem cells from adiposite tissue in patients with Amyotrophic lateral sclerosis", with code CeTMAd/ELA/2011 and EudraCT: 2011-006254-85. Sites participating in this trial: Hospital U. Reina Sofía in Córdoba, Hospital U. Carlos Haya in Málaga and Hospital U. Virgen Macarena in Sevilla. It has been planned to recruit 40 patients with Amyotrophic Lateral Sclerosis. Patients are treated with autologous mesenchymal stem cell derived from adiposite tissue. This investigational product will be manufactured in collaboration with the GMP facility in the Hospital U. Carlos Haya de Málaga.

Immunology

• ¬ Graft Versus Host Disease. Clinical trial titled "Multicentric, randomized, controlled, Phase I/II clinical trial to evaluate the safety and feasibility of therapy with two different doses of autologous mesenchymal stem cells from adipose tissue in patients with extensive chronic graft versus host disease" with code CMM/EICH/2008 and EudraCT: 2008-004015-27. Sites participating in this trial: Hospital U. Virgen de la Nieves de Granada, Hospital U. Virgen del Rocío in Sevilla, Hospital de Jerez de la Frontera, Hospital Clínico in Valencia, Hospital U. Carlos Haya in Malaga and Hospital U. Morales Meseguer in Murcia. It has been planned to recruit 30 patients with graft versus host chronic and severe disease. Patients are treated with alogenic mesenchymal stem cell derived from the fat tissue. This investigational product will be manufactured in collaboration with the GMP facilities in the Unidad de Producción Celular of the Hospital U. Virgen de las Nieves in Granada.

Hematology

Peripheral Vascular Disease 

1. Clinical trial titled "Application of cell regeneration therapy in chronic criticalⁱ limb ischemia syndrome in diabetic patients", with code C/ICPD/2007. Sites participating in this trial: Hospital U. Virgen Macarena and Hospital San Lázaro both located in Sevilla. It was planned to recruit 20 diabetic patients with peripheral vascular disease in lower limbs. Patients have been treated with mononuclear autologous stem cell derived from bone marrow.
2. Clinical trial titled "Phase II clinical trial on therapeutic angiogenesis with autologous bone marrow mononuclear cells in diabetic patients with non-revascularizable chronic critical limb ischemia", with code CMMo/ICPD/2008 and EudraCT: 2008-004064-39. Sites participating in this trial: Hospital U. Reina Sofía in Córdoba,  Hospital U. Virgen del Rocío in Sevilla, Hospital U. San Cecilio in Granada and Hospital U. Morales Meseguer in Murcia. It had been planned to recruit 60 diabetic patients with peripheral vascular disease in lower limbs. Patients are treated with autologous mononuclear stem cell therapy derived from bone marrow.
3. Clinical trial titled "Use of the mesenchymal stem cell from the adipose tissue (CeTMAd) as cell regeneration therapy in chronic critical limb ischemia syndrome in diabetic patients", with code CeTMAd/ICPD/2008 and EudraCT: 2008-001837-88. Sites participating in this trial: Hospital U. Virgen Macarena and Hospital San Lázaro both located in Sevilla. It had been planned to recruit 30 diabetic patients with peripheral vascular disease in lower limbs. Patients are treated with autologous mesenchymal stem cell therapy derived from the fat tissue. This investigational product will be manufactured in collaboration with the GMP facilities in the Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER - Andalusian Centre for Molecular Biology and Regenerative Medicine) located in Sevilla.  
4. Clinical trial titled "Phase II clinical trial on therapeutic angiogenesis with autologous bone marrow mononuclear cells  in non-diabetic patients with non-revascularizable chronic critical limb ischemia" with code CMMon/ICC/2009 and EudraCT: 2009-013636-20. Sites participating in this trial: Hospital U. Reina Sofía in Córdoba, Hospital U. Virgen del Rocío in Sevilla, Hospital U. San Cecilio in Granada, Hospital U. Morales Meseguer in Murcia, Hospital U. Nuestra Señora de Valme in Sevilla, Hospital U. Carlos Haya in Malaga and Hospital Puerta del Mar in Cadiz. It has been planned to recruit 88 diabetic patients with chronic critical lower limbs ischemia. Patients are treated with autologous mononuclear stem cells derived from bone marrow cells.
5. Clinical trial titled “Open, randomized, multicentric phase I/II clinical trial for the study of the use of mesenchymal stem cells from adipose tissue (CeTMAd) as cell regeneration therapy in chronic critical limb ischemia syndrome in non-diabetic patients" with code CeTMAd/ICC/2009 and EudraCT: 2009-013554-32. Sites participating in this trial: Hospital U. Virgen Macarena and Hospital San Lázaro both located in Sevilla. It has been planned to recruit 30 diabetic patients with chronic critical lower limbs ischemia. Patients are treated with autologous mesenchymal stem cell derived from the GMP facilities in the Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER - Andalusian Centre for Molecular Biology and Regenerative Medicine) located in Sevilla.
6. Clinical trial titled: "Open, randomized, multicentric phase I/II, controlled clinical trial for the study of the use of stem cells as cellular therapy in type 2 insulined diabetic patients with chronic critical lower limbs ischemia: study for the insulin needs", with code CeTMMoTa/ICPDI/2010 and EudraCT: 2010-019774-33. Sites participating in this trial: Hospital U. Virgen Macarena and Hospital San Lázaro both located in Sevilla. It has been planned to recruit 48 insulined diabetic patients with chronic critical lower limbs ischemia. Patients are treated with autologous mesenchymal stem cell derived from the GMP facilities in the Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER - Andalusian Centre for Molecular Biology and Regenerative Medicine) located in Sevilla, with autologous mononuclear stem cells from bone marrow cells and with CD133+ endotelial progenitor cells from bone marrow cells derived both from the Hospital U. Reina Sofía in Córdoba

Digestive

• ¬ Hepatic regeneration. Clinical trial titled: "Open, randomized, multicentric phase II clinical trial on the therapeutic use of the intraportal infusion of autologous bone marrow mononuclear cells as potentiator of hepatic regeneration before performing extended hepatic resections" with code CMMo/RH/2009 and EudraCT: 2009-017793-20. Sites participating in this trial: Hospital U.Virgen del Rocío and Hospital U. Nuestra Sra. de Valme (both sites located in Sevilla). It has been planned to recruit 65 patients. Patients are treated with autologous mononuclear stem cells derived from bone marrow cells.

Ophthalmology

• ¬ Corneal Ulcus. Clinical trial titled: "Multicentric clinical trial to evaluate the safety and factibility of an alogenic tissular engineering (nanostructured artificial human cornea) in patients with corneal opaquenesses and/or atrophic corneal ulcus in advanced refractory stages to conventional (ophthalmologic) treatment", phase I-II, with code CAH/ULc/2010 and EudraCT: 2010-024290-40. Sites participating in this trial: Hospital U. San Cecilio in Granada, Hospital U. Virgen de las Nieves in Granada, Hospital U. Virgen del Rocío in Sevilla, Hospital U. Puerta del Mar in Cádiz and Hospital Virgen Macarena in Sevilla. It has been planned to recruit 20 patients with corneal opaquenesses and/or atrophic corneal ulcus in advanced refractory stages. Patients are treated with alogenic tissular engineering (nanostructured artificial human cornea). This investigational product will be manufactured in collaboration with the GMP facilities of the University of Granada as well as with the Centro Regional de Transfusión Sanguínea y Banco de Tejidos de Granada-Almería.

Gastroenterology

• ¬ Faecal Incontinence. Clinical trial titled: "Multicentric, randomized, double blind, phase I/II clinical trial, comparative of two groups of patients to evaluate the safety and efficacy of mesenchymal allogenic stem cells derived from the fat tissue (CMMAd) in the treatment of faecal incontinence", with code CMMAd/InFe/2011 and EudraCT: 2010-021659-17. Sites participating in this trial: Hospital U. Virgen del Rocío in Sevilla and Hospital Juan Ramón Jiménez in Huelva. It has been planned to recruit 16 patients with structural faecal incontinence. Patiens are treated with autologous mesenchymal stem cells derived from fat tissue. This investigational product will be manufactured in collaboration with one of the GMP facilities built in the Hospital U. Carlos Haya in Málaga.

More information: terapias.avanzadas@juntadeandalucia.es